Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study.
Schlam I, Hirko KA, Shveid D, Abuali I, Sewaralthahab S, Nakhils F, Hazra A, Lengyel C, Altuna S, Hussain S, Seid F, Jamil S, Odhiambo A, Leone JP, Metzger O, Abraham J, Soto-Perez-de-Celis E, Chen WY, Block C, Schumer S, Bellon JR, Valenza C, Curigliano G, Tolaney SM, Lynce F, Trapani D. Schlam I, et al. Among authors: lynce f. JCO Glob Oncol. 2024 Dec;10:e2400307. doi: 10.1200/GO-24-00307. Epub 2024 Dec 20. JCO Glob Oncol. 2024. PMID: 39705637
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study.
Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicolò E, Ribeiro JM, Guidi L, Reduzzi C, Spotti M, Adamoli L, Cortès J, Pistilli B, Tolaney SM, Ueno N, Layman RM, Cristofanilli M, Carey LA, Munzone E, Criscitiello C, Lynce F, Woodward WA, Curigliano G. Valenza C, et al. Among authors: lynce f. Eur J Cancer. 2024 Dec;213:115097. doi: 10.1016/j.ejca.2024.115097. Epub 2024 Oct 28. Eur J Cancer. 2024. PMID: 39486164
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Lakhani NJ, Papadopoulos KP, Johnson ML, Park H, Wang D, Yap TA, Dowlati A, Maki RG, Ulahannan S, Lynce F, Kelly K, Williamson S, Malhotra J, Chen S, Gonzalez Ortiz A, Jankovic V, Paccaly A, Masinde S, Mani J, Lowy I, Gullo G, Sims T, Kroog G. Lakhani NJ, et al. Among authors: lynce f. Clin Cancer Res. 2024 Dec 16;30(24):5601-5611. doi: 10.1158/1078-0432.CCR-23-3883. Clin Cancer Res. 2024. PMID: 39422598 Free PMC article. Clinical Trial.
OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. Tolaney SM, et al. Among authors: lynce f. Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26. Future Oncol. 2024. PMID: 38922307 Free PMC article.
Clinicogenomic characterization of inflammatory breast cancer.
Priedigkeit N, Harrison B, Shue R, Hughes M, Li Y, Kirkner GJ, Spurr LF, Remolano MC, Strauss S, Files J, Feeney AM, Grant L, Mohammed-Abreu A, Garrido-Castro A, Sousa RB, Bychkovsky B, Nakhlis F, Bellon JR, King TA, Winer EP, Lindeman N, Johnson BE, Sholl L, Dillon D, Overmoyer B, Tolaney SM, Cherniack A, Lin NU, Lynce F. Priedigkeit N, et al. Among authors: lynce f. bioRxiv [Preprint]. 2024 May 10:2024.05.07.592972. doi: 10.1101/2024.05.07.592972. bioRxiv. 2024. PMID: 38766070 Free PMC article. Preprint.
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. Nat Commun. 2024 May 10;15(1):3957. doi: 10.1038/s41467-024-48359-1. Nat Commun. 2024. PMID: 38730268 Free PMC article. No abstract available.
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S, Jin Q, Vincuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King TA, Weiss A, Partridge AH, Bychkovsky BL, Curigliano G, Tayob N, Lin NU, Garber JE, Tolaney SM, Lynce F. Morganti S, et al. Among authors: lynce f. NPJ Breast Cancer. 2024 Apr 16;10(1):28. doi: 10.1038/s41523-024-00632-8. NPJ Breast Cancer. 2024. PMID: 38627457 Free PMC article.
84 results